105 related articles for article (PubMed ID: 11802275)
21. Fitness of drug-resistant malaria parasites.
Walliker D; Hunt P; Babiker H
Acta Trop; 2005 Jun; 94(3):251-9. PubMed ID: 15845348
[TBL] [Abstract][Full Text] [Related]
22. Plasmodium chabaudi: association of reversal of chloroquine resistance with increased accumulation of chloroquine in resistant parasites.
Miki A; Tanabe K; Nakayama T; Kiryon C; Ohsawa K
Exp Parasitol; 1992 Mar; 74(2):134-42. PubMed ID: 1740175
[TBL] [Abstract][Full Text] [Related]
23. Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
Lopes SC; Blanco YC; Justo GZ; Nogueira PA; Rodrigues FL; Goelnitz U; Wunderlich G; Facchini G; Brocchi M; Duran N; Costa FT
Antimicrob Agents Chemother; 2009 May; 53(5):2149-52. PubMed ID: 19273690
[TBL] [Abstract][Full Text] [Related]
24. Ultrastructural changes associated with reversal of chloroquine resistance by verapamil in Plasmodium chabaudi.
Ohsawa K; Tanabe K; Kimata I; Miki A
Parasitology; 1991 Oct; 103 Pt 2():185-9. PubMed ID: 1745546
[TBL] [Abstract][Full Text] [Related]
25. Different responses of three rodent Plasmodia species, Plasmodium yoelii 17XL, P. berghei NK65 and P. chabaudi AS on treatment with febrifugine and isofebrifugine mixture from Hydrangea macrophylla var. Otaksa leaf in ICR mice.
Ishih A; Miyase T; Ohori K; Terada M
Phytother Res; 2003 Jun; 17(6):650-6. PubMed ID: 12820234
[TBL] [Abstract][Full Text] [Related]
26. Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium.
Min-Oo G; Ayi K; Bongfen SE; Tam M; Radovanovic I; Gauthier S; Santiago H; Rothfuchs AG; Roffê E; Sher A; Mullick A; Fortin A; Stevenson MM; Kain KC; Gros P
Exp Parasitol; 2010 Aug; 125(4):315-24. PubMed ID: 20219464
[TBL] [Abstract][Full Text] [Related]
27. Plasmodium chabaudi: a short-term in vitro culture method and its application to chloroquine resistance testing.
Sohal AK; Arnot DE
Exp Parasitol; 1993 May; 76(3):314-7. PubMed ID: 8500590
[No Abstract] [Full Text] [Related]
28. Structural properties of dibenzosuberanylpiperazine derivatives for efficient reversal of chloroquine resistance in Plasmodium chabaudi.
Osa Y; Kobayashi S; Sato Y; Suzuki Y; Takino K; Takeuchi T; Miyata Y; Sakaguchi M; Takayanagi H
J Med Chem; 2003 May; 46(10):1948-56. PubMed ID: 12723957
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the sensitivity in vitro of Plasmodium falciparum and in vivo of Plasmodium chabaudi Malaria to various drugs and their combinations.
Rahman NN
Med J Malaysia; 1997 Dec; 52(4):390-8. PubMed ID: 10968116
[TBL] [Abstract][Full Text] [Related]
30. Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudi.
Miyata Y; Fujii H; Osa Y; Kobayashi S; Takeuchi T; Nagase H
Bioorg Med Chem Lett; 2011 Aug; 21(16):4710-2. PubMed ID: 21764311
[TBL] [Abstract][Full Text] [Related]
31. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
Burgess SJ; Selzer A; Kelly JX; Smilkstein MJ; Riscoe MK; Peyton DH
J Med Chem; 2006 Sep; 49(18):5623-5. PubMed ID: 16942036
[TBL] [Abstract][Full Text] [Related]
32. Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections.
de Roode JC; Culleton R; Bell AS; Read AF
Malar J; 2004 Sep; 3():33. PubMed ID: 15367331
[TBL] [Abstract][Full Text] [Related]
33. The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Peters W; Stewart LB; Robinson BL
Ann Trop Med Parasitol; 2003 Apr; 97(3):221-36. PubMed ID: 12803854
[TBL] [Abstract][Full Text] [Related]
34. Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
He Z; Qin L; Chen L; Peng N; You J; Chen X
Antimicrob Agents Chemother; 2008 Jul; 52(7):2653-6. PubMed ID: 18443126
[TBL] [Abstract][Full Text] [Related]
35. Blockade of TNF receptor 1 reduces disease severity but increases parasite transmission during Plasmodium chabaudi chabaudi infection.
Long GH; Chan BH; Allen JE; Read AF; Graham AL
Int J Parasitol; 2008 Jul; 38(8-9):1073-81. PubMed ID: 18226816
[TBL] [Abstract][Full Text] [Related]
36. Antimalarial drugs clear resistant parasites from partially immune hosts.
Cravo P; Culleton R; Hunt P; Walliker D; Mackinnon MJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2897-901. PubMed ID: 11557487
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics of chloroquine in healthy and Plasmodium chabaudi-infected mice: implications for chronotherapy.
Cambie G; Verdier F; Gaudebout C; Clavier F; Ginsburg H
Parasite; 1994 Sep; 1(3):219-26. PubMed ID: 9140488
[TBL] [Abstract][Full Text] [Related]
38. Interruption of the blood-stage cycle of the malaria parasite, Plasmodium chabaudi, by protein tyrosine kinase inhibitors.
Gazarini ML; Garcia CR
Braz J Med Biol Res; 2003 Nov; 36(11):1465-9. PubMed ID: 14576900
[TBL] [Abstract][Full Text] [Related]
39. Taxol arrests the development of blood-stage Plasmodium falciparum in vitro and Plasmodium chabaudi adami in malaria-infected mice.
Pouvelle B; Farley PJ; Long CA; Taraschi TF
J Clin Invest; 1994 Jul; 94(1):413-7. PubMed ID: 7913713
[TBL] [Abstract][Full Text] [Related]
40. Identification of gametocyte-associated pir genes in the rodent malaria parasite, Plasmodium chabaudi chabaudi AS.
Cunningham DA; Reid AJ; Hosking C; Deroost K; Tumwine-Downey I; Sanders M; Langhorne J
BMC Res Notes; 2023 Apr; 16(1):56. PubMed ID: 37076932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
